This site contains promotional content intended for UK Healthcare Professionals and other relevant decision makers | Not a HCP? Visit our  Public Site.
Adverse Event reporting can be found at the bottom of the page | Prescribing Information for the relevant medicine can be found adjacent to the below content and/or in the footer below. 

Cardiovascular
Cardiovascular
Womens Health
Women's Health
two kidneys
Nephrology
Oncology
Oncology
Ophthalmology
Ophthalmology
Respiratory
Respiratory
Bayer for ProfessionalsYour Resource Portal

P3 Prostate Cancer Forum: 2024

Session 3 - Mapping the Journey: Strategies and RWE in nmCRPC

P3 background - Article

In session 3, we gained insights into nmCRPC patients in the UK, and discussed how the treatment paradigm is shifting in this patient group, as next-generation imaging becomes increasingly available and primary treatment choices are changing. 

 

nmCRPC in the UK – Let's Discuss – Professor Rob Jones

NUBEQA  (darolutamide) Prescribing Information

Xofigo▼ (radium-223 dichloride) Prescribing Information

Meeting Summary Downloadable

Download the summary below for the key takeaways from this meeting.

Visit here

Speakers

Session 4 - Looking ahead: confronting the challenges of mCRPC

In session 4, we took a deep dive into mCRPC, the latest therapies and data and key considerations for treatment sequencing in this patient group

Watch here
Session 4: Confronting the challenges of mCRPC
we took a deep dive into mCRPC; the latest therapies, data and key considerations for treatment sequencing.
PP-NUB-GB-2019, January 2025
Register your interest to P3 2025 now!
Register your interest in attending the P3 2025 meeting
PP-NUB-GB-1919, October 2024
P3 Prostate Cancer Forum: 2024
perspectives, possibilities, progress
PP-NUB-GB-2012, January 2025

PP-NUB-GB-2017, January 2025